FDA Grants Sobi's Pacritinib Fast Track Status For VEXAS Syndrome

Swedish Orphan Biovitrum received FDA Fast Track Designation for pacritinib as a treatment for VEXAS syndrome. The designation may accelerate regulatory interactions and development timelines for the rare-disease therapy, representing a positive clinical and regulatory catalyst for Sobi.